Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + Ganetespib + Paclitaxel + Radiotherapy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Ganetespib||STA-9090||HSP90 Inhibitor 35||Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (PMID: 26244021).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Carboplatin + Ganetespib + Paclitaxel + Radiotherapy||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Ganetespib had a variable impact on chemoradiation therapy (consisting of Paraplatin (carboplatin), Taxol (paclitaxel), and radiation) in non-small cell lung cancer cell lines in culture and in xenograft models, resulting in increased sensitivity in some cell lines, and decreased sensitivity in others (PMID: 27354472).||27354472|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|